584 Views | 752 Downloads
Corresponding author: Lisa A Jackson (Email: jackson.l@ghc.org)
All authors participated in the design, implementation, analysis and interpretation of the study.
All authors read and approved the final manuscript.
LF and NB were involved in all phases of the study, and led the clinical team at GSK Biologicals.
LAJ, MJG and HLK led the clinical team at their respective centers, JB conducted the data analysis.
JJT managed the team responsible for detailed antigenic characterization and vaccine match analysis.
We are grateful to the National Institute for Biological Standards and Control (NIBSC, UK) for providing the vaccine virus strains.
The authors are indebted to the participating clinicians, sub-investigators, nurses, research coordinators, and laboratory technicians at the study site and the sponsor's project staff for their support and contributions throughout the study.
We also want to thank the study volunteers.
We would like to thank the laboratory staff for their excellent, sedulous immunological laboratory work.
Finally we would like to thank Annick Moon (independent, UK) for her assistance in preparing the manuscript and Isabelle Camby for coordination.
GSK Biologicals was the funding source and was involved in all stages of the study conduct and analysis. GSK Biologicals also took in charge all costs associated with the development and the publishing of this manuscript. The corresponding author had full access to the data, and final responsibility for submission of the manuscript for publication.
LJ has received research funding from manufacturers of influenza vaccines, including GSK, Sanofi Pasteur, and Novartis and has served as a consultant to GSK and Novartis.
Dr Harry Keyserling received grant support from GlaxoSmithKline to conduct the study.
JB has no conflict of interest to declare.
NB is a former employee of GlaxoSmithKline Biologicals and reports ownership of equity or stock options.
LFF is a full-time employee of GlaxoSmithKline.
JT discloses having received laboratory support from GSK and MerciaPharma, as well as clinical trial support from Protein Sciences Corporation, Vaxinnate, Ligocyte, Wyeth, Bavarian Nordic, Sanofi and PaxVax. JT discloses scientific advisory board activities for Immune Targeting Systems and Toyama Chemical Concern.
© 2010 Jackson et al; licensee BioMed Central Ltd